Dechra Pharmaceuticals PLC

LSE:DPH (UK)   Ordinary Shares
£ 38.66 (+0.05%) Jan 15
At Loss
P/B:
5.83
Market Cap:
£ 4.40B ($ 5.59B)
Enterprise V:
£ 4.83B ($ 6.14B)
Volume:
-
Avg Vol (2M):
-
Also Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Dechra Pharmaceuticals PLC ( ) from 2000 to May 20 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Dechra Pharmaceuticals PLC stock (LSE:DPH) PE ratio as of May 20 2024 is 0. More Details

Dechra Pharmaceuticals PLC (LSE:DPH) PE Ratio (TTM) Chart

To

Dechra Pharmaceuticals PLC (LSE:DPH) PE Ratio (TTM) Historical Data

Total 1170
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 13
Dechra Pharmaceuticals PLC PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-21 At Loss 2023-11-08 At Loss
2024-01-15 At Loss 2023-11-07 At Loss
2024-01-12 At Loss 2023-11-06 At Loss
2024-01-11 At Loss 2023-11-03 At Loss
2024-01-10 At Loss 2023-11-02 At Loss
2024-01-09 At Loss 2023-11-01 At Loss
2024-01-08 At Loss 2023-10-31 At Loss
2024-01-05 At Loss 2023-10-30 At Loss
2024-01-04 At Loss 2023-10-27 At Loss
2024-01-03 At Loss 2023-10-26 At Loss
2024-01-02 At Loss 2023-10-25 At Loss
2023-12-29 At Loss 2023-10-24 At Loss
2023-12-28 At Loss 2023-10-23 At Loss
2023-12-27 At Loss 2023-10-20 At Loss
2023-12-22 At Loss 2023-10-19 At Loss
2023-12-21 At Loss 2023-10-18 At Loss
2023-12-20 At Loss 2023-10-17 At Loss
2023-12-19 At Loss 2023-10-16 At Loss
2023-12-18 At Loss 2023-10-13 At Loss
2023-12-15 At Loss 2023-10-12 At Loss
2023-12-14 At Loss 2023-10-11 At Loss
2023-12-13 At Loss 2023-10-10 At Loss
2023-12-12 At Loss 2023-10-09 At Loss
2023-12-11 At Loss 2023-10-06 At Loss
2023-12-08 At Loss 2023-10-05 At Loss
2023-12-07 At Loss 2023-10-04 At Loss
2023-12-06 At Loss 2023-10-03 At Loss
2023-12-05 At Loss 2023-10-02 At Loss
2023-12-04 At Loss 2023-09-29 At Loss
2023-12-01 At Loss 2023-09-28 At Loss
2023-11-30 At Loss 2023-09-27 At Loss
2023-11-29 At Loss 2023-09-26 At Loss
2023-11-28 At Loss 2023-09-25 At Loss
2023-11-27 At Loss 2023-09-22 At Loss
2023-11-24 At Loss 2023-09-21 At Loss
2023-11-23 At Loss 2023-09-20 At Loss
2023-11-22 At Loss 2023-09-19 At Loss
2023-11-21 At Loss 2023-09-18 At Loss
2023-11-20 At Loss 2023-09-15 At Loss
2023-11-17 At Loss 2023-09-14 At Loss
2023-11-16 At Loss 2023-09-13 At Loss
2023-11-15 At Loss 2023-09-12 At Loss
2023-11-14 At Loss 2023-09-11 At Loss
2023-11-10 At Loss 2023-09-08 At Loss
2023-11-09 At Loss 2023-09-07 At Loss

Dechra Pharmaceuticals PLC (LSE:DPH) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.